北京锤特生物科技

Triton Biopharma is a Beijing-based biotechnology company specializing in next-generation gene editing technologies, including CRISPR/Cas, base editing, and prime editing. The company focuses on developing one-time curative therapies for genetic disorders, particularly in the fields of ophthalmology, metabolic diseases, and hematology. Triton leverages its proprietary editing platforms and delivery systems, such as lipid nanoparticles (LNPs), to target specific organs like the liver and the eye. Their pipeline includes programs for hypercholesterolemia and various inherited retinal diseases like Leber congenital amaurosis. The company is backed by prominent venture capital firms including Legend Capital and IDG Capital, aiming to translate cutting-edge genomic research into clinical applications.